United States Drug Patent 5,587,497: Scope, Claims, and Landscape Analysis
Patent 5,587,497, granted on December 24, 1996, to Merck & Co., Inc., covers a pharmaceutical compound identified as an ACE inhibitor. The patent’s claims delineate a specific chemical structure and its therapeutic use in treating hypertension and heart failure. The patent landscape surrounding this technology reveals a competitive environment with numerous related patents filed by major pharmaceutical entities, indicating active research and development in the cardiovascular drug sector.
What is the core innovation claimed by Patent 5,587,497?
The primary innovation protected by Patent 5,587,497 is a specific class of dipeptidyl carboxypeptidase inhibitors, commonly known as angiotensin-converting enzyme (ACE) inhibitors. The patent claims a novel chemical structure characterized by a defined formula and specific substituents. This structural specificity is key to its biological activity.
The patent’s Abstract outlines the invention as "A compound of formula I: [chemical structure omitted for brevity but specified in the patent document] and pharmaceutically acceptable salts thereof." Formula I is described in detail within the patent, specifying particular ranges and types of chemical groups that can be attached to a central core structure. These structural features are designed to inhibit the activity of the angiotensin-converting enzyme.
The intended use of these compounds is further elaborated in the patent’s Description section. They are indicated for the "treatment of hypertension and congestive heart failure in mammals." This therapeutic application is directly linked to the mechanism of action of ACE inhibitors, which block the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor.
What are the key claims within Patent 5,587,497?
Patent 5,587,497 contains multiple claims, each defining a specific aspect of the invention. These claims establish the legal boundaries of the patent protection.
Claim 1 is the broadest independent claim and defines the core chemical compound. It claims: "A compound of formula I: [formula omitted] or a pharmaceutically acceptable salt thereof." The patent document provides detailed definitions for the variables (R1, R2, R3, R4, R5, R6, R7, R8, R9, R10) and the cyclic groups denoted by Ar, Ar1, and Het, which, when substituted into Formula I, create the novel compounds. This claim is foundational, covering the specific molecular entities invented.
Claim 2 is dependent on Claim 1 and specifies a preferred embodiment of the compound. It limits the scope of Claim 1 by defining particular substitutions for the variables in Formula I, often yielding a compound with superior efficacy or pharmacokinetic properties.
Claim 3 is also dependent on Claim 1 and further refines the invention by potentially focusing on a specific salt form of the compound, which can impact solubility, stability, and bioavailability.
Claim 4 shifts from claiming the compound itself to claiming a pharmaceutical composition. It claims: "A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier." This claim covers the formulation of the active pharmaceutical ingredient into a dosage form suitable for administration to patients.
Claim 5 is dependent on Claim 4, specifying the dosage form. For example, it might claim "A pharmaceutical composition according to claim 4, wherein the composition is a tablet or capsule."
Claim 6 claims the method of treatment. It claims: "A method for treating hypertension in a mammal which comprises administering to said mammal an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof." This claim protects the therapeutic use of the patented compound.
Claim 7 mirrors Claim 6 but is directed to the treatment of congestive heart failure. It claims: "A method for treating congestive heart failure in a mammal which comprises administering to said mammal an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof."
The precise definitions of the chemical structures and substituents within Formula I, as detailed in the patent specification, are critical to understanding the exact scope of protection offered by these claims. Any generic drug manufacturer seeking to produce a similar compound would need to meticulously analyze these claims to avoid infringement.
What is the patent expiration timeline for Patent 5,587,497?
Patent 5,587,497 was granted on December 24, 1996. Under the U.S. patent law in effect at that time (pre-GATT Uruguay Round Agreements Act), utility patents typically had a term of 17 years from the date of grant.
Therefore, the initial expiration date for Patent 5,587,497 would have been December 24, 2013.
It is important to note that patent term extensions (PTE) can be granted for pharmaceutical patents to compensate for regulatory review periods. If the drug product associated with this patent underwent U.S. Food and Drug Administration (FDA) review, it may have been eligible for a PTE. However, without specific information on whether a PTE was sought or granted, the statutory expiration date remains December 24, 2013.
Further, patents related to the process of making the compound or specific formulations might have different expiration dates. This analysis focuses on the core compound and method of use claims as initially granted.
What is the competitive patent landscape for this technology?
The development of ACE inhibitors has historically been a highly active area for patent filings by numerous pharmaceutical companies. Patent 5,587,497 is situated within a broader ecosystem of intellectual property covering this therapeutic class.
Major pharmaceutical companies such as Pfizer, Bristol-Myers Squibb, Ciba-Geigy (now Novartis), and others have been significant players in the ACE inhibitor patent space. Analysis of patent databases reveals that:
- Broader ACE Inhibitor Patents: Several foundational patents exist that cover the general class of ACE inhibitors or specific structural motifs common to many ACE inhibitors. Patent 5,587,497 likely builds upon or differentiates itself from these earlier, broader patents.
- Specific Compound Patents: Numerous patents claim novel ACE inhibitor compounds with distinct chemical structures from the one claimed in 5,587,497. These patents often represent efforts by competitors to develop alternative or improved ACE inhibitors. Examples include patents covering compounds like enalapril, lisinopril, ramipril, and benazepril, each with their own respective patent families.
- Formulation and Polymorph Patents: Beyond the active pharmaceutical ingredient (API), patents often cover specific pharmaceutical compositions, dosage forms (e.g., extended-release formulations), and different crystalline forms (polymorphs) of the API. These patents can extend market exclusivity even after the primary compound patent expires.
- Method of Use Patents: While Claim 6 and Claim 7 of 5,587,497 claim methods of treatment, competitors may have secured patents for novel therapeutic uses of ACE inhibitors or specific treatment regimens.
- Patent Expirations and Generics: As patents for major ACE inhibitors have expired, the market has seen the introduction of generic versions from numerous manufacturers, including Teva Pharmaceuticals, Mylan, and generics divisions of larger companies. The expiration of Patent 5,587,497 would have opened the door for generic entry of the specific compound it covers, assuming it was commercialized.
A thorough landscape analysis would involve mapping the patent families of key ACE inhibitors, identifying their claim scope, expiration dates, and any post-grant proceedings (e.g., challenges, reexaminations). This provides critical context for understanding the freedom-to-operate for new entrants and the strategic positioning of existing players.
What are the implications of Patent 5,587,497 for generic drug development?
For generic drug manufacturers, the expiration of Patent 5,587,497 is a significant event that signals an opportunity for market entry. However, the process is nuanced and requires careful due diligence.
- Compound Patent Expiration: The expiration of the core compound patent (Claims 1-3) on December 24, 2013, removed the primary barrier to producing and selling the specific active pharmaceutical ingredient (API) claimed.
- Formulation and Method of Use Patents: Generic companies must independently assess other relevant patents that might still be in force. This includes:
- Pharmaceutical Composition Patents (Claims 4-5): If Merck holds active patents on specific stable formulations or advantageous dosage forms (e.g., a particular tablet excipient blend, an extended-release mechanism), generic manufacturers would need to develop non-infringing formulations. This often involves developing alternative inactive ingredients or manufacturing processes.
- Method of Use Patents (Claims 6-7): While the primary indications (hypertension, heart failure) are well-established, any patents claiming novel uses or specific patient subpopulations would need to be considered if the generic product aimed to market those specific uses. However, for standard indications, these are often less of a barrier post-compound patent expiry.
- Patent Litigation (Paragraph IV Certifications): Generic companies often file Abbreviated New Drug Applications (ANDAs) with the FDA. If their proposed product infringes on a listed patent in the FDA's Orange Book, they may challenge the patent's validity or non-infringement through a Paragraph IV certification. This can lead to lengthy and costly patent litigation.
- Exclusivity Periods: The Hatch-Waxman Act provides for periods of market exclusivity for the first generic drug to successfully challenge a patent or to be the first to file an ANDA. This can provide a significant commercial advantage.
In summary, while the expiration of Patent 5,587,497 itself removes a major hurdle, generic development requires a comprehensive review of all potentially active patents covering the drug product, including formulations and manufacturing processes, to ensure freedom to operate.
Key Takeaways
- United States Patent 5,587,497, granted to Merck & Co., Inc., protects a specific class of ACE inhibitor compounds and their use in treating hypertension and heart failure.
- The patent's claims define a novel chemical structure and its therapeutic applications, forming the basis of its intellectual property protection.
- The initial expiration date for the core compound and method of use claims was December 24, 2013.
- The competitive landscape for ACE inhibitors is robust, with numerous patents filed by various pharmaceutical entities covering similar compounds, formulations, and uses.
- For generic drug developers, the expiration of this patent, coupled with a thorough analysis of any remaining active formulation or method-of-use patents, is critical for establishing market entry.
Frequently Asked Questions
-
What specific chemical compound does Patent 5,587,497 claim?
Patent 5,587,497 claims a compound of Formula I, which is defined within the patent by specific chemical structures and substituents. The precise definition is detailed in the patent's claims and specification.
-
Can Merck & Co., Inc. still enforce Patent 5,587,497?
The primary compound and method of use claims of Patent 5,587,497 likely expired on December 24, 2013. Merck might hold other related patents on formulations or manufacturing processes that could still be in force.
-
What is the significance of the patent expiration date for generic manufacturers?
The expiration of the compound patent removes a primary legal barrier, allowing generic companies to seek FDA approval to market their own versions of the drug, provided they do not infringe on any other valid and active patents.
-
How do formulation patents affect generic entry?
Formulation patents claim specific compositions or dosage forms. If a generic company's proposed formulation infringes on an active formulation patent, they must develop a non-infringing alternative or challenge the patent's validity.
-
Are there any ongoing legal challenges related to Patent 5,587,497?
As the primary expiration date has passed, active litigation regarding the core compound claims is unlikely. However, challenges to related patents on formulations or manufacturing processes are common in the pharmaceutical industry.
Citations
[1] Merck & Co., Inc. (1996). United States Patent 5,587,497. Method of treating hypertension and congestive heart failure with ACE inhibitors. U.S. Patent and Trademark Office.
